FindTrial
Sign In

C21

DRUG7 trials

Sponsors

Vicore Pharma AB

Conditions

COVID-19COVID-19 PneumoniaEndothelial DysfunctionIdiopathic Pulmonary FibrosisRaynaud PhenomenonStudy Vasodilatory Effects of C21Systemic SclerosisType2diabetes

Phase 1

Effect of C21 on Forearm Blood Flow
CompletedNCT05277922
Vicore Pharma ABStudy Vasodilatory Effects of C21
Start: 2022-04-28End: 2022-05-18Updated: 2025-04-23
A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
CompletedNCT05831644
Vicore Pharma ABEndothelial Dysfunction, Type2diabetes
Start: 2023-03-31End: 2023-06-20Updated: 2024-11-12

Phase 2

Cold Challenge With C21 in RP
CompletedNCT04388176
Vicore Pharma ABRaynaud Phenomenon, Systemic Sclerosis
Start: 2020-01-03End: 2020-12-14Updated: 2023-05-18
Safety and Efficacy of C21 in Subjects With COVID-19
CompletedNCT04452435
Vicore Pharma ABCOVID-19
Start: 2020-07-21End: 2020-10-13Updated: 2021-06-23
Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
CompletedNCT04533022
Vicore Pharma ABIdiopathic Pulmonary Fibrosis
Start: 2020-11-13End: 2024-03-30Updated: 2025-05-23

Phase 3

A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
CompletedNCT04880642
Vicore Pharma ABCOVID-19
Start: 2021-09-16End: 2022-04-25Updated: 2023-12-14

Unknown Phase

Retrospective Evaluation of Lung Pathology in Subjects With COVID-19
CompletedNCT04878913
Vicore Pharma ABCOVID-19, COVID-19 Pneumonia
Start: 2021-07-07End: 2021-08-23Updated: 2024-09-04

Related Papers

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
2024-01-0316 citations
Late Breaking Abstract - Characterization of high responders in the phase 2a IPF AIR trial of C21 using baseline quantitative CT image analysis
2023-09-09
Investigation of the effect of the angiotensin II type 2 receptor (AT2R) agonist C21 on plasma NT-proBNP, a diagnostic biomarker, in subjects hospitalised with COVID-19
European Heart Journal2022-10-01
A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s
Lara D. Veeken2022-07-2716 citations
Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial.
2021-10-2436 citations
Neurologic Manifestations of COVID-19 in Children: Emerging Pathophysiologic Insights
Pediatric Critical Care Medicine2021-05-0739 citations